Advertisement
Getting Tie(2)d up in angiogenesis
Markus Ramsauer and Patricia A. D’Amore
Schepens Eye Research Institute, and Harvard Medical School, Boston, Massachusetts, USA
Address correspondence to: Patricia A. D’Amore, Schepens Eye Research Institute, 20 Staniford Street, Boston, Massachusetts 02114, USA. Phone: (617) 912-2559; Fax: (617) 912-0128; E-mail: pdamore@vision.eri.harvard.edu.
Find articles by Ramsauer, M. in: JCI | PubMed | Google Scholar
Schepens Eye Research Institute, and Harvard Medical School, Boston, Massachusetts, USA
Address correspondence to: Patricia A. D’Amore, Schepens Eye Research Institute, 20 Staniford Street, Boston, Massachusetts 02114, USA. Phone: (617) 912-2559; Fax: (617) 912-0128; E-mail: pdamore@vision.eri.harvard.edu.
Find articles by D’Amore, P. in: JCI | PubMed | Google Scholar
Published December 1, 2002 - More info
J Clin Invest. 2002;110(11):1615–1617. https://doi.org/10.1172/JCI17326.
© 2002 The American Society for Clinical Investigation
Angiogenesis, the growth of new vessels from pre-existing blood vessels, requires complex signaling pathways and a high degree of spatial and temporal coordination among various cell types, multiple pro- and anti-angiogenic factors, and their corresponding receptors. Although the targeted disruption of many of these factors leads to embryonic lethal defects in vascular development, the precise actions of these factors at the cellular and molecular levels are not completely defined. Such is the case for angiopoietin-1 (Ang1), angiopoietin-2 (Ang2) and the Ang receptor Tie2. Mice deficient in Ang1, Ang2, or Tie2 exhibit aberrant vascular development, characterized by abnormal interactions between endothelial cells (ECs) and their supporting cells. The abluminal cells of the vasculature, which includes pericytes in the microvasculature and smooth muscle cells (SMCs) in large vessels, are collectively referred to as mural cells (reviewed in ref. 1). In this issue of the JCI, Uemura and colleagues provide some insight into the mechanisms that underlie these defects (2). The authors demonstrate that whereas blocking the function of the PDGF β receptor (PDGFR-β) in the developing retinal vasculature led to mural cell-deficient vessels that were poorly remodeled and leaky, administration of recombinant modified angiopoietin-1 (Ang1*) restored the vascular structure of the larger vessels in the absence of the mural cells.
-
Vessel assembly
The relevance of this observation is best appreciated in the context of the complexity of vessel assembly. During vascularization, a capillary plexus formed by vasculogenesis is remodeled via proliferation and migration of ECs (Figure 1). VEGF is essential in both developmental and postnatal (normal and pathologic) angiogenesis (reviewed in ref. 3). During murine retinal vascularization, the developmental process used by Uemura and coworkers, growth of the vessel sprouts is directed by astrocyte production of VEGF (4). It is important to point out that the site of VEGF production varies among tissues and reflects tissue architecture (discussed in ref. 5). The nascent vessel is then modeled from its immature, unstable state to a mature, stable state. Proliferating ECs secrete PDGF-B, which acts as a chemoattractant and mitogen for undifferentiated mural cell precursors (6, 7). Mice deficient in PDGF-B or the PDGFR-β display aberrant vessel remodeling and an absence of pericytes in the microvasculature (8). Tissue culture studies have demonstrated that contact between the ECs and newly-arrived mural cell precursors leads to the activation of TGF-β1, which inhibits EC proliferation and migration (9, 10), reduces VEGF receptor 2 (VEGFR2) expression on ECs (11), and induces the differentiation of perivascular cells to a pericyte/SMC fate (6). In support of a key role for TGF-β1, the targeted disruption of TGF-β1, TGF-βR2 or the co-receptor endoglin, leads to defects in vascular development, apparently due to defects in epithelial-mesenchymal interactions (12–14).
Figure 1The multifactorial regulation of vessel assembly. The upper panel summarizes observations obtained using tissue culture models and knockout mice. Formation of a primary capillary network is initiated by VEGF-induced proliferation and migration of endothelial cells (ECs). Endothelial secretion of PDGF-B attracts mesenchymal cells, which contact the EC. Contact between the ECs and mesenchymal cells activates TGF-β1, which suppresses endothelial proliferation and migration, induces mural cell differentiation, and is associated with vessel maturation. The lower panel illustrates findings in experimental models in which levels of angiopoietins were manipulated by exogenous administration. Addition of Ang1 results in stabilization of vessels in the absence of pericytes, whereas addition of Ang2 induces vessel regression in the absence of VEGF (–) and sprouting in the presence of VEGF (+).
Recent studies have shown that concomitant with their differentiation, pericytes are induced to express VEGF, which may contribute to vessel stability by replacing VEGF supplied by the developing tissue itself (Darland and D’Amore, unpublished observations). The concept of VEGF dependence of nascent vessels is supported by several observations. Inhibition of endogenous VEGF in the pupillary membrane, a transient ocular microvessel network, via introduction of soluble VEGFR2, resulted in a significant increase in the number of apoptotic ECs (15). In addition, examination of new vessels induced in adult heart or liver by tissue-specific overexpression of VEGF revealed “a critical transition point beyond which remodeled new vessels persisted for months” in the absence of exogenous VEGF, whereas earlier withdrawal of VEGF led to vessel regression (16). Although not directly assessed in this study, the authors speculated that pericyte/SMC association with vessels would be associated with the observed functional stability. Interestingly, we have observed that pericytes associated with newly formed retinal vessels express VEGF, perhaps providing one mechanism by which the vessel stability is accomplished (Darland and D’Amore, unpublished observations).
Copyright © 2024 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)